The study explores the effects of a dual-targeting glycomimetic antagonist,
GMI-1757, combined with anti-
PD-L1 therapy on
pancreatic tumor progression in mice. An orthotopic
pancreatic carcinoma model was utilized, where mice were treated with either a control solution or GMI-1757, followed by anti-PD-L1 or an isotype control antibody. The experiment was divided into four groups, with different combinations of treatments. Bioluminescence imaging was employed to monitor
tumor activity, and the study concluded with tissue analysis for
fibrosis and immune cell infiltration.
The results indicated that mice treated with the isotype control experienced tumor growth, while those treated with anti-PD-L1 showed tumor growth arrest. Most notably, the combination of GMI-1757 and anti-PD-L1 led to tumor regression in a majority of the mice. Histopathological evaluation revealed that GMI-1757 reduced fibrosis within the tumors and enhanced immune cell infiltration. The study suggests that the dual antagonist could potentially improve the effectiveness of anti-PD-L1 therapy by reducing tumor fibrosis and increasing immune cell presence. Further research is being conducted on the synergistic effects of GMI-1757 with other immunotherapies to counteract the negative impacts of fibrosis and limited host cell infiltration on tumor response.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
